🌎 Amicus Therapeutics Upgraded, BioNTech Initiated, CRH Initiated and more…
RJ Hamster
Ratings changes for Amicus Therapeutics, BioNTech, Fortrea, Aethlon Medical, Perion Network, Payoneer Global, Chord Energy and more…Upgrade to MarketBeat All Access to get early delivery, personalized stock alerts, portfolio monitoring tools, and more. Start Your Free Trial.
Bitcoin has surged past $70,000. Are you prepared for what’s next? Our free guide, “Navigating the Future: A Comprehensive Guide to Cryptocurrency Investments in 2024,” is essential for staying ahead in the fast-evolving crypto market. It’s crafted for both beginners and seasoned investors. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.
A brand-new guide from the host of one of the world’s largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today’s crypto market.
Director Jonathan Rubinstein sold 5,264 shares of the business’s stock in a transaction dated Thursday, May 9th. The shares were sold at an average price of $190.00, for a total transaction of $1,000,160.00. Following the transaction, the director now directly owns 104,400 shares in the company, valued at approximately $19,836,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Director John L. Hennessy sold 1,500 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $168.08, for a total value of $252,120.00. Following the sale, the director now owns 4,391 shares in the company, valued at approximately $738,039.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Microsoft Co. (NASDAQ:MSFT) declared a quarterly dividend on Tuesday, March 12th. Shareholders of record on Thursday, May 16th will be paid a dividend of 0.75 per share by the software giant on Thursday, June 13th. This represents a $3.00 annualized dividend and a yield of 0.73%. The ex-dividend date of this dividend is Wednesday, May 15th.
Atmos Energy (NYSE:ATO) was upgraded by analysts at Wells Fargo & Company from an “equal weight” rating to an “overweight” rating. They now have a $132.00 price target on the stock, up previously from $130.00. This represents a 12.8% upside from the current price of $116.97.
Enhabit (NYSE:EHAB) was upgraded by analysts at SVB Leerink LLC from an “underperform” rating to a “market perform” rating. They now have a $8.50 price target on the stock. This represents a 6.4% downside from the current price of $9.08.
Edison International (NYSE:EIX) was upgraded by analysts at Wells Fargo & Company from an “equal weight” rating to an “overweight” rating. They now have a $86.00 price target on the stock, up previously from $72.00. This represents a 15.1% upside from the current price of $74.71.
Edwards Lifesciences (NYSE:EW) was upgraded by analysts at Deutsche Bank Aktiengesellschaft from a “hold” rating to a “buy” rating.The current price is $85.34.
Expeditors International of Washington (NASDAQ:EXPD) was upgraded by analysts at BNP Paribas from an “underperform” rating to a “neutral” rating. They now have a $112.00 price target on the stock. This represents a 5.0% downside from the current price of $117.95.
Amicus Therapeutics (NASDAQ:FOLD) was upgraded by analysts at Guggenheim from a “neutral” rating to a “buy” rating. They now have a $13.00 price target on the stock. This represents a 40.5% upside from the current price of $9.25.
Fortrea (NASDAQ:FTRE) was upgraded by analysts at Robert W. Baird from a “neutral” rating to an “outperform” rating. They now have a $36.00 price target on the stock, down previously from $45.00. This represents a 24.8% upside from the current price of $28.85.
Newell Brands (NASDAQ:NWL) was upgraded by analysts at Barclays PLC from an “underweight” rating to an “equal weight” rating. They now have a $8.00 price target on the stock. This represents a 7.4% downside from the current price of $8.64.
Planet Fitness (NYSE:PLNT) was upgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating. They now have a $78.00 price target on the stock, up previously from $68.00. This represents a 18.1% upside from the current price of $66.03.
Boston Beer (NYSE:SAM) was upgraded by analysts at Jefferies Financial Group Inc. from a “hold” rating to a “buy” rating. They now have a $360.00 price target on the stock, up previously from $335.00. This represents a 26.3% upside from the current price of $285.00.
Sarepta Therapeutics (NASDAQ:SRPT) was upgraded by analysts at Oppenheimer Holdings Inc. from a “market perform” rating to an “outperform” rating. They now have a $180.00 price target on the stock. This represents a 36.9% upside from the current price of $131.53.
Neuronetics (NASDAQ:STIM) was upgraded by analysts at William Blair from a “market perform” rating to an “outperform” rating.The current price is $2.53.
VTEX (NYSE:VTEX) was upgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating. They now have a $9.00 price target on the stock. This represents a 27.7% upside from the current price of $7.05.
Expro Group (NYSE:XPRO) was upgraded by analysts at Barclays PLC from an “equal weight” rating to an “overweight” rating. They now have a $27.00 price target on the stock, up previously from $18.00. This represents a 28.8% upside from the current price of $20.96.
AirSculpt Technologies (NASDAQ:AIRS) was downgraded by analysts at SVB Leerink LLC from an “outperform” rating to a “market perform” rating. They now have a $5.00 price target on the stock, down previously from $8.25. This represents a 12.4% upside from the current price of $4.45.
Augmedix (NASDAQ:AUGX) was downgraded by analysts at Evercore ISI from an “outperform” rating to an “inline” rating. They now have a $1.50 price target on the stock, down previously from $5.00. This represents a 27.1% upside from the current price of $1.18.
Augmedix (NASDAQ:AUGX) was downgraded by analysts at Maxim Group from a “buy” rating to a “hold” rating. They now have a $5.00 price target on the stock. This represents a 323.7% upside from the current price of $1.18.
Jackson Financial (NYSE:JXN) was downgraded by analysts at Keefe, Bruyette & Woods from an “outperform” rating to a “market perform” rating.The current price is $75.05.
Inotiv (NASDAQ:NOTV) was downgraded by analysts at Jefferies Financial Group Inc. from a “buy” rating to a “hold” rating. They now have a $3.75 price target on the stock, down previously from $11.50. This represents a 72.0% upside from the current price of $2.18.
Shimmick (NASDAQ:SHIM) was downgraded by analysts at Craig Hallum from a “buy” rating to a “hold” rating.The current price is $2.70.
Shimmick (NASDAQ:SHIM) was downgraded by analysts at Roth Mkm from a “buy” rating to a “neutral” rating. They now have a $3.50 price target on the stock, down previously from $9.00. This represents a 29.6% upside from the current price of $2.70.
Arcellx (NASDAQ:ACLX) is now covered by analysts at Evercore ISI. They set an “outperform” rating and a $85.00 price target on the stock. This represents a 70.6% upside from the current price of $49.81.
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) is now covered by analysts at Stephens. They set an “overweight” rating and a $25.00 price target on the stock. This represents a 149.8% upside from the current price of $10.01.
BridgeBio Pharma (NASDAQ:BBIO) is now covered by analysts at Evercore ISI. They set an “outperform” rating and a $50.00 price target on the stock. This represents a 74.0% upside from the current price of $28.73.
BioMarin Pharmaceutical (NASDAQ:BMRN) is now covered by analysts at Evercore ISI. They set an “outperform” rating and a $113.00 price target on the stock. This represents a 41.6% upside from the current price of $79.78.
BioNTech (NASDAQ:BNTX) is now covered by analysts at Evercore ISI. They set an “inline” rating and a $100.00 price target on the stock. This represents a 8.5% upside from the current price of $92.16.
Blueprint Medicines (NASDAQ:BPMC) is now covered by analysts at Stephens. They set an “overweight” rating and a $140.00 price target on the stock. This represents a 31.9% upside from the current price of $106.15.
Perspective Therapeutics (NYSEAMERICAN:CATX) is now covered by analysts at Royal Bank of Canada. They set an “outperform” rating and a $3.00 price target on the stock.
CI&T (NYSE:CINT) is now covered by analysts at UBS Group AG. They set a “neutral” rating and a $4.20 price target on the stock. This represents a 19.3% upside from the current price of $3.52.
CRH (NYSE:CRH) is now covered by analysts at Royal Bank of Canada. They set an “outperform” rating and a $110.00 price target on the stock. This represents a 33.8% upside from the current price of $82.19.
CEMEX (NYSE:CX) is now covered by analysts at Royal Bank of Canada. They set an “underperform” rating and a $9.00 price target on the stock. This represents a 14.4% upside from the current price of $7.87.
Delcath Systems (NASDAQ:DCTH) is now covered by analysts at Stephens. They set an “overweight” rating and a $25.00 price target on the stock. This represents a 248.2% upside from the current price of $7.18.
The Descartes Systems Group (NASDAQ:DSGX) (TSE:DSG) is now covered by analysts at Redburn Atlantic. They set a “neutral” rating and a $90.00 price target on the stock. This represents a 5.0% downside from the current price of $94.78.
Elevation Oncology (NASDAQ:ELEV) is now covered by analysts at Stephens. They set an “overweight” rating and a $8.00 price target on the stock. This represents a 125.4% upside from the current price of $3.55.
Exelixis (NASDAQ:EXEL) is now covered by analysts at Stephens. They set an “equal weight” rating and a $23.00 price target on the stock. This represents a 10.5% upside from the current price of $20.82.
Inovio Pharmaceuticals (NASDAQ:INO) is now covered by analysts at Stephens. They set an “overweight” rating and a $20.00 price target on the stock. This represents a 78.1% upside from the current price of $11.23.
Manhattan Associates (NASDAQ:MANH) is now covered by analysts at Redburn Atlantic. They set a “buy” rating and a $260.00 price target on the stock. This represents a 20.6% upside from the current price of $215.62.
Moderna (NASDAQ:MRNA) is now covered by analysts at Evercore ISI. They set an “in-line” rating and a $120.00 price target on the stock. This represents a 6.9% downside from the current price of $128.94.
Neurocrine Biosciences (NASDAQ:NBIX) is now covered by analysts at Evercore ISI. They set an “outperform” rating and a $175.00 price target on the stock. This represents a 29.2% upside from the current price of $135.45.
Nurix Therapeutics (NASDAQ:NRIX) is now covered by analysts at Stephens. They set an “overweight” rating and a $20.00 price target on the stock. This represents a 34.0% upside from the current price of $14.93.
Orion Group (NYSE:ORN) is now covered by analysts at Craig Hallum. They set a “buy” rating and a $14.00 price target on the stock. This represents a 60.4% upside from the current price of $8.73.
Regeneron Pharmaceuticals (NASDAQ:REGN) is now covered by analysts at Evercore ISI. They set an “outperform” rating and a $1,150.00 price target on the stock. This represents a 17.5% upside from the current price of $978.63.
Sensei Biotherapeutics (NASDAQ:SNSE) is now covered by analysts at Stephens. They set an “overweight” rating and a $5.00 price target on the stock. This represents a 226.8% upside from the current price of $1.53.
SPS Commerce (NASDAQ:SPSC) is now covered by analysts at Redburn Atlantic. They set a “buy” rating and a $220.00 price target on the stock. This represents a 12.1% upside from the current price of $196.27.
Seagate Technology (NASDAQ:STX) is now covered by analysts at Citigroup Inc.. They set a “buy” rating and a $110.00 price target on the stock. This represents a 15.3% upside from the current price of $95.39.
Veru (NASDAQ:VERU) is now covered by analysts at B. Riley. They set a “buy” rating and a $5.00 price target on the stock. This represents a 250.9% upside from the current price of $1.43.
Vermilion Energy (NYSE:VET) (TSE:VET) is now covered by analysts at BMO Capital Markets. They set an “outperform” rating on the stock.The current price is $12.03.
Western Digital (NASDAQ:WDC) is now covered by analysts at Citigroup Inc.. They set a “buy” rating and a $90.00 price target on the stock. This represents a 24.7% upside from the current price of $72.19.
Weatherford International (NASDAQ:WFRD) is now covered by analysts at Citigroup Inc.. They set a “buy” rating and a $155.00 price target on the stock. This represents a 24.8% upside from the current price of $124.16.
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
Upgrade to MarketBeat All Access and receive your premium edition of MarketBeat Daily at 9:00 AM ET.
UPGRADE NOW
Manage Your Watchlist
View and add up to five holdings to your watchlist.
VIEW MY PORTFOLIO
Join Our Facebook Group
Join MarketBeat’s free stock discussion and trading idea group on Facebook.
JOIN NOW
Thank you for subscribing to MarketBeat!
We empower individual investors to make better trading decisions by providing real-time financial information and objective market research. MarketBeat is a small business and email is a crucial tool for us to share information, news, trading ideas and financial products and services with our subscribers (that’s you!). If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com.
